Document:

EX-10.10

 Exhibit 10.10 

July 9, 2021 
 Keegan Harper 

Via email 
 Dear Keegan: 

Nalu Medical, Inc. (the “Company”) is pleased to offer you the position of Executive Chairperson of the Company (or such other title as mutually
agreed between you and the Company). In your new position, you will report directly to the Company’s board of directors (the “Board”). If you accept this offer, your start date with the Company will be July 9, 2021, 2021 (the
“Start Date”). 
 In addition, you will continue to be a member of the Board while you remain an employee of the Company, subject to any required
stockholder approval. For the avoidance of doubt, assuming the Board is divided into classes with three year expected terms, it is expected that your position on the Board will next be submitted to a vote of the stockholders at the annual meeting of
stockholders to be held in 2023. 
 Except as otherwise agreed to by the Board, if your employment with the Company terminates or is terminated for any
reason, you will resign from all director and officer positions with the Company and any of its subsidiaries. 
 As an employee of the Company, you will
perform such services and responsibilities as reasonably determined and assigned by the Board or its representative in its sole discretion, provided that such services and responsibilities are expected to require approximately 8 hours per week.
During the period you are employed with the Company in this position (the “Employment Period”), you will be permitted to engage in the activities set forth on Appendix A. Except as otherwise previously disclosed to the Board, you will not
engage in any other business, job or consulting activity during the Employment Period without the written permission of the Board. 
 The compensation and
benefits terms of this offer are as follows: 
  

	 	1.	 You will receive an annual salary of $150,000, paid in accordance with the Company’s normal payroll
practices. Your position is exempt from eligibility for overtime. 

  

	 	2.	 On the pricing date of the Company’s first initial public offering in connection with the filing of a
registration statement on Form S-1 with the U.S. Securities and Exchange Commission, and subject to your continued employment with the Company through that date, you will be granted a Company stock option (the
“IPO Option”) covering a number of shares of the Company’s common stock such that the grant date fair value of the IPO Option for U.S. generally accepted accounting principles will be approximately $1,000,000. The exercise price of
the IPO Option will be the price per share of the initial public offering. Subject to Schedule 1, 1/16 of shares subject to the IPO Option will vest monthly from the grant date through the one year anniversary of the date of grant, and 1/48
of shares subject to the IPO Option will vest monthly following the one year anniversary through the two year anniversary of the date of grant, provided you remain a Service Provider (as defined in the 2021 Plan) through the applicable vesting date.
The Option will be governed by the terms and conditions of the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), and a stock option agreement thereunder in the Company’s standard form. Any future Company equity
awards will be determined by the Board, in its discretion. 

  

	 	3.	 As an employee of the Company, you will be eligible to participate in all Company-sponsored benefits currently
and hereafter maintained by the Company for the benefit of the Company’s senior executives, subject to the satisfaction of any eligibility requirements and compliance with the terms of those benefit programs. You will be eligible to receive the
severance benefits under Schedule 1, subject to the terms and conditions of Schedule 1, which are incorporated by reference herein. The Company may modify salary, bonus, and benefits from time-to-time as it deems necessary, subject to your ability to resign for “Good Reason” under Schedule 1. 

 Keegan Harper 

Page 2 
  

 As a Company employee, you will be expected to abide by the Company’s rules and standards. Specifically,
you will be required to sign an acknowledgment that you have read and that you understand the Company’s rules of conduct which are included in the Company’s employee handbook. 

As a condition of your employment, you are also required to sign and comply with the Company’s At-Will
Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (the “Confidentiality Agreement”). 
 Your employment with
the Company is “at will.” This means that, as an employee, you have the right to terminate your employment at any time, for any reason, with or without notice. Similarly, the Company may terminate your employment at any time, with or
without cause or prior notice. Our at-will policy cannot be altered except by a written agreement to that effect signed by both you and a member of the Board other than you. 

You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its
compensation policies in a manner that minimizes your tax liabilities. 
 You agree that any and all controversies, claims, or disputes with anyone
(including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from your service to the Company, will be subject to arbitration
in accordance with the arbitration agreement set forth in provisions of the Confidentiality Agreement. 
 You acknowledge that Wilson Sonsini
Goodrich & Rosati, Professional Corporation, is representing only the Company in the negotiation of this letter. You acknowledge that you have had the opportunity to discuss this letter with and obtain advice from your private attorney,
have had sufficient time to, and have carefully read and fully understand all the provisions of this letter, and are knowingly and voluntarily entering into this letter. 

This letter (including its schedules and exhibits), along with the Confidentiality Agreement and all other plans and agreements referenced herein, set forth
the terms of your employment with the Company and supersede any prior representations or agreements including, but not limited to, your Consulting Agreement with the Company dated July 1, 2020. This offer is valid until July 9, 2021. We
must receive your written acceptance of this offer no later than 5:00pm Pacific Time that day. 

 Keegan Harper 

Page 3 
  

 Please accept this offer by signing below and returning this letter via email to me. 

Sincerely, 
 /s/ Earl Fender 

Earl Fender 
 On behalf of Nalu Medical, Inc. 

 

					
			
	/s/ Keegan Harper	 		 	July 9, 2021
	Keegan Harper	 		 	Date
			
	July 9, 2021	 		 	  

	Start Date	 		 	

 Schedule 1 

Unless otherwise defined in this Schedule 1, capitalized terms shall have the meanings given to them in the letter to which this schedule is
attached. 
  

	 	1.	 Involuntary Termination.    In the event of an Involuntary Termination, then, subject to
Section 2 below, you will receive: 

  

	 	a.	 accelerated vesting as to 100% of the unvested shares subject to any of your outstanding Company equity awards
(including, but not limited to, the IPO Option and any other options to purchase common stock of the Company) as of immediately prior to your Termination Date. In the case of an equity award with performance-based vesting, unless otherwise specified
in the applicable equity award agreement governing such award, all performance goals and other vesting criteria will be deemed achieved at target. 

  

	 	b.	 A lump sum cash payment equal to the sum of (1) $300,000 less (2) the aggregate amount of salary
payments paid to you pursuant to this letter; for the avoidance of doubt, if you experience an Involuntary Termination following the two year anniversary of the Start Date, it is expected that no cash severance will be provided to you pursuant to
this Section 1(b). 

  

	 	2.	 Conditions to Receipt of Severance Benefits. 

 

	 	a.	 The receipt of any severance benefits pursuant to Section 1 of this Schedule 1 will be subject to you
signing and not revoking a customary separation agreement and release of claims in the Company’s standard form (the “Release”) and provided that such Release becomes effective and irrevocable no later than 60 days following the
Termination Date (such deadline, the “Release Deadline”). If the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any rights to benefits under this Schedule 1. In no event will the severance
benefits be provided until the Release becomes effective and irrevocable. 

  

	 	b.	 Any lump sum payments under Section 1(b) will be provided on the first regularly scheduled payroll date of
the Company following the date the Release becomes effective and irrevocable (the “Severance Date”), subject to any delay required by Section 3 below. 

 

	 	c.	 Your receipt of any severance payments or benefits upon an Involuntary Termination under Section 1 is
subject to you returning all documents and other property provided to you by the Company (with the exception of a copy of the Company employee handbook and personnel documents specifically relating to you), developed or obtained by you in connection
with your employment with the Company, or otherwise belonging to the Company. 

  

	 	3.	 Section 409A. The parties agree that this letter (including all of its schedules and exhibits) shall be
interpreted to comply with or be exempt from Section 409A of the Internal Revenue Code of 1986 (as it has been and may be amended from time to time) (the “Code”) and any regulations and guidance that have been promulgated or may be
promulgated from time to time thereunder at the time of your termination (“Section 409A”), so that none of the severance payments or benefits provided hereunder will be subject to the additional tax imposed under Section 409A,
and any ambiguities or ambiguous terms herein will be interpreted to so comply or be so exempt. For purposes of determining entitlement to severance benefits that could otherwise be subject to Section 409A, a termination of employment shall not
be deemed to have occurred unless the termination is also a “separation from service” within the meaning of Section 409A. If you are a “specified employee” within the meaning of Section 409A, then the severance and any
other separation benefits payable to you upon your separation from service (whether under this letter or otherwise) to the extent that the same constitute deferred compensation under Section 409A (the “Deferred Payments”), otherwise
due to you on or within the 6-month period following your separation from service will accrue during such 6-month period and will become payable in a lump sum

	 	
payment on the date 6 months and one day following the date of your separation from service (such rule, the “Six Month Delay Rule”) or, if earlier, the date of your death. All
subsequent Deferred Payments following the application of the Six Month Delay Rule, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit or, if earlier, upon the date of your death. In the event your
Termination Date occurs at a time during the calendar year where the Release Deadline is in the calendar year following the calendar year in which your Termination Date occurs, then any severance payments or benefits under this Schedule 1 that would
be considered Deferred Payments will be paid on, or in the case of installments, will not commence until, the 61st day after your Termination Date, or such later date as provided in this section.
Each payment and benefit payable under this letter is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. In no event will the Company or its
successor reimburse or indemnify you for any taxes or other obligations that may arise under Section 409A. All payments made under this letter shall be subject to reduction to reflect taxes or other charges required to be withheld by law, and
you will be solely responsible for any and all taxes arising in connection with this letter and compensation paid or payable to you, including but not limited to any taxes, penalties and interest, if any, arising under Section 409A.

  

	 	4.	 Change in Control Acceleration. In the event the Company experiences a Change in Control, and you remain a
Service Provider through the date of such Change in Control, 100% of the then outstanding and unvested shares subject to each of your Company equity awards (including, but not limited to, the IPO Option and any other options to purchase common stock
of the Company) will accelerate and fully vest. In the case of an equity award with performance-based vesting, unless otherwise specified in the applicable equity award agreement governing such award, all performance goals and other vesting criteria
will be deemed achieved at target. 

  

	 	5.	 Definitions 

  

	 	a.	 Cause means the occurrence of any of the following: (1) your willful failure to substantially
perform your duties to the Company or other lawful duties assigned to you by the Board, other than a failure resulting from your Disability, (2) a willful act by you that constitutes gross misconduct and which is injurious to the Company,
(3) your willful breach of a material provision of the Confidentiality Agreement or any written agreement between you and the Company, or (4) your material and willful violation of a federal or state law or regulation applicable to the
business of the Company. 

  

	 	b.	 Change in Control means “Change in Control” as defined under the 2021 Plan.

  

	 	c.	 Disability means a total and permanent disability as defined in Section 22(e)(3) of the Code.

  

	 	d.	 Good Reason means the termination of your employment with the Company by you in accordance with the next
sentence after the occurrence of one or more of the following events without your express written consent: (1) a material reduction by the Company of your annual base salary as in effect immediately prior to such reduction (other than in
connection with a general reduction of base salaries applicable to all employees in similar positions), (2) a material diminution of your authority, job duties or responsibilities, provided that in the event a Change in Control occurs neither a mere
change in title alone nor reassignment to a position that is substantially similar to the position held prior to such Change of Control in terms of duties and/or responsibilities shall constitute a material diminution, or (3) a change in the
location of your employment of more than 40 miles from the Company’s current location. You may not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting the grounds for “Good
Reason” within 90 days of their initial occurrence, a reasonable cure period of not less than 30 days following the date of such notice and your resignation occurs within 30 days following the end of such cure period if the “Good
Reason” conditions remain uncured. 

	 	e.	 Involuntary Termination means your termination of employment from the Company as a result of either:

  

	 	1.	 the Company’s termination of your employment for any reason other than for Cause, death or Disability;
or  

  

	 	2.	 your resignation for Good Reason. 

 

	 	f.	 Termination Date means the date your employment with the Company terminates.EX-10.11

 Exhibit 10.11 

NALU MEDICAL, INC. 

Confirmatory Employment Letter 

July 2, 2021 
 Earl Fender 

Dear Mr. Earl Fender: 
 This letter
agreement (the “Agreement”) is entered into between Nalu Medical, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the date of the first sale of common equity securities of
the Company to the general public upon the closing of an underwritten public offering (1) pursuant to an effective registration statement filed pursuant to Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended, and
(2) immediately after which such securities are registered on a national securities exchange (as defined under then-applicable United States federal securities laws and regulations) (such date, the “Effective Date”). The
purpose of this Agreement is to confirm the current terms and conditions of your employment. 
 1. Position. Your current title is
President and Chief Executive Officer of the Company. This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether
full-time or part-time) without the prior approval of the Company’s Board of Directors (the “Board”). By signing this Agreement, you confirm to the Company that you have no contractual
commitments or other legal obligations that would prohibit you from performing your duties for the Company. 
 2. Compensation and
Benefits. 
 (a) Base Salary. Your rate of annual base salary as of the Effective Date will be $520,000 per year, less applicable
withholding, which will be paid in accordance with the Company’s normal payroll procedures 
 (b) Annual Bonus Opportunity. Your
annual target bonus opportunity following the Effective Date will be seventy-five percent (75%) of your annual base salary (the “Target Bonus”). The Target Bonus shall be subject to review and may be adjusted based upon the
Company’s normal performance review practices. Your actual bonuses shall be based upon achievement of performance objectives to be determined by the Board in its sole and absolute discretion. Bonuses will be paid as soon as practicable after
the Board determines that such bonuses have been earned, but in no event will a bonus be paid to you after the later of (i) the fifteenth (15th) day of the third (3rd) month following the close of the Company’s fiscal year in which such
bonus is earned or (ii) March 15 following the calendar year in which such bonus is earned. 

 (c) Employee Benefits. As a full-time employee, you will continue to be eligible to
participate in the Company’s standard benefit plans as in effect from time to time, on the same basis as those benefit plans are generally made available to other similarly situated executives of the Company. Such benefit plans are subject to
change, and may be supplemented, altered, or eliminated, in part or entirely. Any eligibility to participate in such benefits plans, as well as the terms thereof, shall be as set forth in the governing documents for such plans, or there are no such
governing documents, in the Company’s policies. 
 (d) Equity Awards. You will be eligible to receive compensatory equity awards
such as stock options or restricted stock unit awards from the Company on the terms and conditions determined by the Board in its sole discretion. 

(e) Expenses. You will be entitled to receive prompt reimbursement for all reasonable expenses incurred by you in the furtherance of or
in connection with the performance of your duties hereunder, in accordance with the applicable policy of the Company, as in effect from time to time. In the event that any expense reimbursements are taxable to you, such reimbursements will be made
in the time frame specified by Treasury Regulation Section 1.409A-3(i)(1)(iv) unless another time frame that complies with or is exempt from Section 409A is specified in the Company’s expense
reimbursement policy. 
 (f) Vacation. You will be entitled to accrue paid vacation in accordance with the Company’s vacation
policy, as in effect from time to time. 
 3. Severance & Change of Control Benefits. In connection with
executing this Agreement, you are also entering into the Change in Control and Severance Agreement between you and the Company (the “Severance Agreement”), which is incorporated herein by reference. 

4. Proprietary Information and Inventions Agreement. As an employee of the Company, you will continue to have access to certain
confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company. To protect the interests of the Company, your acceptance of this Agreement
reaffirms that the terms of the Company’s At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement that you executed on April 15, 2020 (the
“Confidentiality Agreement”) continue to be in effect. 
 5. At-Will
Employment. You acknowledge and agree that your employment with the Company will be “at-will” employment and may be terminated at any time with or without cause or notice. You understand and
agree that neither your job performance nor commendations, bonuses, or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of your employment with the
Company. You further acknowledge and agree that the Company may modify job titles, salaries and benefits from time to time as it deems necessary. However, as described in this Agreement, you may be eligible to receive severance benefits under the
Severance Agreement depending on the circumstances of the termination of your employment with the Company. 

 6. Tax Matters. 

(a) Withholding. All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be
withheld by law, and you will be solely responsible for any and all taxes arising in connection with this Agreement and compensation paid or payable to you, including but not limited to any taxes, penalties and interest, if any, arising under
Section 409A. 
 (b) Section 409A. The Company intends that all payments and benefits provided under this Agreement or otherwise
are exempt from, or comply with, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and any final regulations and guidance thereunder and any applicable state law equivalent, as each may be amended or promulgated
from time to time (“Section 409A”) so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities will be interpreted to so
be exempt or comply. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 

(c) Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the
Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities. 
 7. Entire Agreement,
Amendment and Enforcement. This Agreement, the Severance Agreement and the Confidentiality Agreement supersede and replace any prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and the
Company, and constitute the complete agreement between you and the Company regarding the subject matter set forth herein. This Agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized
officer of the Company. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the principles of conflict of laws thereof. 

8. Miscellaneous. 
 (a)
Arbitration. You that any and all controversies, claims, or disputes with anyone (including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of,
relating to, or resulting from your service to the Company, will be subject to arbitration in accordance with the provisions of the Confidentiality Agreement. 

(b) Protected Activity. You acknowledge and understand that nothing in this Agreement, the Confidentiality Agreement, or any other
agreement between you and the Company limits or prohibits you from filing and/or pursuing a charge or complaint with, or otherwise communicating or cooperating with or participating in any investigation or proceeding that may be conducted by, any
federal, state or local government agency or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor

 
Relations Board, including disclosing documents or other information as permitted by law, without giving notice to, or receiving authorization from, the Company. In addition, nothing in this
Agreement, the Confidentiality Agreement, or any other agreement between you and the Company is intended to limit employees’ rights to discuss the terms, wages, and working conditions of their employment, nor to deny employees the right to
disclose information pertaining to sexual harassment or any unlawful or potentially unlawful conduct, as protected by applicable law. You acknowledge and understand that you are not permitted to disclose the Company’s attorney-client privileged
communications or attorney work product. In addition, you acknowledge that the Company has provided you with notice in compliance with the Defend Trade Secrets Act of 2016, regarding immunity from liability for limited disclosures of trade secrets,
attached as Schedule A hereto. 
 (c) Successors. In addition to any obligations imposed by law upon any successor to the
Company, the Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform this
Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 

(d) Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, which shall remain in full force and effect. 
 (e) Counterparts. This Agreement may be
executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. 

(f) Acknowledgment. You acknowledge that you have had the opportunity to discuss this Agreement with and obtain advice from your
private attorney, have had sufficient time to, and have carefully read and fully understand all the provisions of this Agreement, and are knowingly and voluntarily entering into this Agreement. 

* * * * * 
 We are extremely
excited about your continued employment with the Company! 

 Please indicate your acceptance of this Agreement, and confirmation that it contains our
complete agreement regarding the terms and conditions of your employment, by signing the bottom portion of this Agreement and returning a copy to me. 
  

			
	Very truly yours,
	
	NALU MEDICAL, INC.
		
	By:	 	/s/ Jeff Swiecki

  

			
	I have read and accept this Agreement:
	
	/s/ Earl Fender
	Earl Fender

			
		
	Dated:	 	July 2, 2021

 Schedule A 

SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 states that “ . . . [a]n individual shall not be held criminally or civilly liable under any Federal or
State trade secret law for the disclosure of a trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of
reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an
employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade
secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]